eFFECTOR Therapeutics, Inc., listed on the Nasdaq Stock Market LLC, is set to be removed from listing effective at the opening of the trading session on July 29, 2024. The Nasdaq Staff made the determination to delist the company's securities after a review indicated that eFFECTOR Therapeutics no longer met the requirements for listing, specifically citing Listing Rules 5101, 5605(b)(1), 5605(c)(2), 5605(d)(2), 5605(e)(1), and 5550(b)(2). The company was initially notified of this decision on June 24, 2024, and following the lack of an appeal to the Hearings Panel, the securities were suspended on July 3, 2024. The delisting decision became final on the same day of the suspension.

eFFECTOR Therapeutics, Inc., listed on the Nasdaq Stock Market LLC, is set to be removed from listing effective at the opening of the trading session on July 29, 2024. The Nasdaq Staff made the determination to delist the company's securities after a review indicated that eFFECTOR Therapeutics no longer met the requirements for listing, specifically citing Listing Rules 5101, 5605(b)(1), 5605(c)(2), 5605(d)(2), 5605(e)(1), and 5550(b)(2). The company was initially notified of this decision on June 24, 2024, and following the lack of an appeal to the Hearings Panel, the securities were suspended on July 3, 2024. The delisting decision became final on the same day of the suspension.